ES2972799T3 - Combinación farmacéutica de un compuesto de artemisinina, ácido 5-aminolevulínico o ácido metil-5-aminolevulínico y un agente quimioterapéutico - Google Patents

Combinación farmacéutica de un compuesto de artemisinina, ácido 5-aminolevulínico o ácido metil-5-aminolevulínico y un agente quimioterapéutico Download PDF

Info

Publication number
ES2972799T3
ES2972799T3 ES21705541T ES21705541T ES2972799T3 ES 2972799 T3 ES2972799 T3 ES 2972799T3 ES 21705541 T ES21705541 T ES 21705541T ES 21705541 T ES21705541 T ES 21705541T ES 2972799 T3 ES2972799 T3 ES 2972799T3
Authority
ES
Spain
Prior art keywords
artemisinin
cancer
pharmaceutical composition
aminolevulinic acid
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21705541T
Other languages
English (en)
Spanish (es)
Inventor
Ulrich Elling
Josef Penninger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jlp Health GmbH
Original Assignee
Jlp Health GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jlp Health GmbH filed Critical Jlp Health GmbH
Application granted granted Critical
Publication of ES2972799T3 publication Critical patent/ES2972799T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ES21705541T 2020-02-19 2021-02-18 Combinación farmacéutica de un compuesto de artemisinina, ácido 5-aminolevulínico o ácido metil-5-aminolevulínico y un agente quimioterapéutico Active ES2972799T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20158341.6A EP3868372A1 (en) 2020-02-19 2020-02-19 A pharmaceutical combination of an artemisinin compound and a heme synthesis modulator for treating cancer
PCT/EP2021/054039 WO2021165405A1 (en) 2020-02-19 2021-02-18 A pharmaceutical combination of an artemisinin compound, 5-aminolevulinic acid or methyl-5-aminolevulinic acid and a chemotherapeutic agent

Publications (1)

Publication Number Publication Date
ES2972799T3 true ES2972799T3 (es) 2024-06-17

Family

ID=69779738

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21705541T Active ES2972799T3 (es) 2020-02-19 2021-02-18 Combinación farmacéutica de un compuesto de artemisinina, ácido 5-aminolevulínico o ácido metil-5-aminolevulínico y un agente quimioterapéutico

Country Status (15)

Country Link
US (1) US20230121771A1 (https=)
EP (2) EP3868372A1 (https=)
JP (1) JP7719787B2 (https=)
KR (1) KR20220143097A (https=)
CN (1) CN114786661A (https=)
AU (1) AU2021222339A1 (https=)
BR (1) BR112022014692A2 (https=)
CA (1) CA3165208A1 (https=)
DK (1) DK3989961T3 (https=)
ES (1) ES2972799T3 (https=)
FI (1) FI3989961T3 (https=)
IL (1) IL294856A (https=)
PL (1) PL3989961T3 (https=)
PT (1) PT3989961T (https=)
WO (1) WO2021165405A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220184234A1 (en) * 2020-11-30 2022-06-16 Sonalasense, Inc. Metabolic targeting of low grade tumors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU225148B1 (en) 1995-03-10 2006-07-28 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy or diagnosis, products and kits comprising thereof and method of in vitro diagnosis by their using
GB0018528D0 (en) 2000-07-27 2000-09-13 Photocure Asa Compounds
GB0406917D0 (en) 2004-03-26 2004-04-28 Photocure Asa Compounds
TWI482621B (zh) * 2009-12-23 2015-05-01 Sigma Tau Ind Farmaceuti 青蒿素基藥物與其他化學治療劑的抗癌組合物
JP2011225471A (ja) * 2010-04-16 2011-11-10 Univ Of Tsukuba 抗癌剤の効果増強剤
US10925963B2 (en) * 2015-06-22 2021-02-23 Washington University Combination artemisinin and chemiluminescent photodynamic therapy and uses therefor
CN105963244A (zh) * 2016-01-15 2016-09-28 赵鸣 注射用青蒿琥酯制剂及其应用
CN106527586B (zh) * 2016-11-04 2019-09-06 吉林省北方医药有限责任公司 一种移动终端设备
CN108570089B (zh) * 2017-04-28 2019-10-29 云白药征武科技(上海)有限公司 双氢青蒿素-甾体结合物及其制备方法和应用
GB201800736D0 (en) * 2018-01-17 2018-02-28 St Georges Hospital Medical School Combination therapy for treatment of leukemia
CN108635581A (zh) * 2018-05-23 2018-10-12 昆药集团股份有限公司 一种组合物及其在制备治疗肿瘤的药物中的应用

Also Published As

Publication number Publication date
KR20220143097A (ko) 2022-10-24
PL3989961T3 (pl) 2024-04-08
IL294856A (en) 2022-09-01
CA3165208A1 (en) 2021-08-26
CN114786661A (zh) 2022-07-22
JP2023514426A (ja) 2023-04-05
AU2021222339A1 (en) 2022-07-28
EP3989961A1 (en) 2022-05-04
PT3989961T (pt) 2024-02-26
EP3868372A1 (en) 2021-08-25
WO2021165405A1 (en) 2021-08-26
EP3989961B1 (en) 2023-11-22
BR112022014692A2 (pt) 2022-09-20
US20230121771A1 (en) 2023-04-20
FI3989961T3 (fi) 2024-02-14
JP7719787B2 (ja) 2025-08-06
DK3989961T3 (da) 2024-01-29

Similar Documents

Publication Publication Date Title
ES2881048T3 (es) Bisaminoquinolinas asimétricas y bisaminoquinolinas con enlazadores variados como inhibidores de la autofagia para el cáncer y otras terapias
JP2009543770A (ja) Ｃｄｋ及びｇｓｋの阻害のためのピラゾール誘導体の組合せ剤
Kaur et al. Titanium wire implants with nanotube arrays: A study model for localized cancer treatment
CN116096704A (zh) 用于治疗癌症的组合疗法
CN105492011A (zh) 不理想给药化学化合物的治疗增效
AU2014299699A1 (en) Use of eribulin and lenvatinib as combination therapy for treatment of cancer
ES2828033T3 (es) Pautas posológicas de melflufen para el cáncer
ES2988496T3 (es) Compuestos y métodos para tratar el cáncer
TW201121956A (en) Use of N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in the treatment of antimitotic agent resistant cancer
TW201217361A (en) Method of treating abnormal cell growth
ES2972799T3 (es) Combinación farmacéutica de un compuesto de artemisinina, ácido 5-aminolevulínico o ácido metil-5-aminolevulínico y un agente quimioterapéutico
US20260091021A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
Rastegar-Pouyani et al. Repurposing the anti-parasitic agent pentamidine for cancer therapy; a novel approach with promising anti-tumor properties
ES2931104T3 (es) Uso de 2-fenil-6-(1H-imidazol-1-il)quinazolina para el tratamiento de enfermedades neurodegenerativas, preferentemente la enfermedad de Alzheimer
ES2343674T3 (es) Farmacos preventivos o curativos para el endometriosis.
TW201000116A (en) Peptide compound and use thereof
ES3038469T3 (en) Quinoline derivative and epirubicin used for soft tissue sarcoma combination therapy
US8729080B2 (en) Cancer therapy
ES2978336T3 (es) Combinación de un inhibidor de Mcl-1 y midostaurina, usos y composiciones farmacéuticas de la misma
RU2847295C1 (ru) Фармацевтическая комбинация соединения артемизинина, 5- аминолевулиновой кислоты или метил-5-аминолевулиновой кислоты и химиотерапевтического агента
HK40074153B (en) A pharmaceutical combination of an artemisinin compound, 5-aminolevulinic acid or methyl-5-aminolevulinic acid and a chemotherapeutic agent
HK40074153A (en) A pharmaceutical combination of an artemisinin compound, 5-aminolevulinic acid or methyl-5-aminolevulinic acid and a chemotherapeutic agent
CN111840289A (zh) 用于治疗骨巨细胞瘤的喹啉类化合物或其药学上可接受的盐
ES2309222T3 (es) Inhibidores no nucleosidos de la transcriptasa inversa como antagonistas de la proliferacion celular e inductores de la diferenciacion celular.
JP7603605B2 (ja) 非定型プロテインキナーゼｃの阻害剤およびヘッジホッグ経路依存性癌の治療におけるその使用